The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies DOI Open Access
Hitoshi Iwasaki, Hiroaki Yagyu, Hitoshi Shimano

et al.

Journal of Atherosclerosis and Thrombosis, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), is a pervasive chronic disease that affects millions of people worldwide. It predisposes individuals to range severe microvascular and macrovascular complications, which drastically impact the patient's quality life increase mortality rates owing various comorbidities. This extensive review explores intricate pathophysiology underlying diabetic focusing on key mechanisms, such as atherosclerosis, insulin resistance, inflammation, endothelial dysfunction. also highlights recent therapeutic advancements, including introduction SGLT2 inhibitors GLP-1 receptor agonists, provide benefits beyond glycemic control offer cardiovascular renal protection. Furthermore, future position agonists in terms prevention diseases will be discussed. Considering differences secretion capacity between Western Asian patients, Japanese we propose treatment strategy for high-quality Japan.

Language: Английский

Citations

1
The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

Citations

0